Aardvark Therapeutics, Inc. 8-K

What Happened
Aardvark Therapeutics, Inc. filed an 8-K on June 12, 2026 reporting that on June 10, 2026 it entered into retention bonus agreements with CFO/COO Nelson Sun and CMO Manasi Jaiman. The two executives are eligible for cash retention bonuses that together total $703,500, payable in full on January 1, 2027, subject to continued employment and other conditions.

Key Details

• Nelson Sun (CFO & COO) retention bonus: $346,500 total = $198,000 guaranteed 2026 annual bonus + $148,500 retention bonus.
• Manasi Jaiman, M.D., M.P.H. (CMO) retention bonus: $357,000 total = $204,000 guaranteed 2026 annual bonus + $153,000 retention bonus.
• Full payment scheduled January 1, 2027, contingent on each executive remaining employed through that date.
• If the company terminates an executive without “Cause” or the executive resigns for “Good Reason” before Jan 1, 2027, the company will pay the full bonus early, subject to the executive signing a prescribed release of claims.
• The actual retention agreements will be filed with Aardvark’s Form 10-Q for the quarter ending June 30, 2026.

Why It Matters
These retention payments signal the company is taking steps to keep key financial and clinical leadership in place, which can be important for continuity during clinical development and corporate execution. For investors, the items represent potential near-term cash compensation of $703,500 and will appear in future SEC filings (the Form 10-Q) with the full agreement terms.